This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Major histocompatibility complex class I deficiency주조직적합성복합체 I형 결핍

ICD-10: D81.6 | Synonyms: MHC class I deficiency, TAP deficiency, Bare lymphocyte syndrome type I, TAP1/TAP2/Tapasin deficiency

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

First description

Major histocompatibility complex (MHC) class I deficiency became known when Touraine et al. in 1985 first reported an unusual immunodeficient patient whose cell surfaces did not express HLA class I antigens. It was initially called 'Bare lymphocyte syndrome (BLS)', the name originating from the phenotypic feature that MHC class I molecules are not detected on the lymphocyte surface.

Identification of the molecular cause

In the 1990s it was established that cell surface expression of MHC class I molecules requires not only expression of the HLA genes themselves but also antigen presentation-related transporter proteins (TAP1, TAP2, Tapasin). De la Salle et al. in 1994 first reported that TAP1 gene variants cause MHC class I deficiency, and cases due to TAP2 and Tapasin (TAPBP) variants were subsequently reported.

Separation from MHC class II deficiency

BLS was initially a concept in which MHC class I and II deficiencies were used interchangeably, but as advances in molecular genetics showed that the two diseases have completely different etiologies, they were separated into BLS type I (MHC I deficiency) and BLS type II (MHC II deficiency).

Situation in Korea

In Korea, MHC class I deficiency is reported very rarely, and a small number of cases have been diagnosed through primary immunodeficiency centers. Cases registered in rare disease registries are extremely limited.

2. Causes

MHC class I antigen presentation pathway

MHC class I molecules present intracellular peptides (viral, tumor antigens, etc.) to CD8+ T cells, inducing cytotoxic immune responses. Normal MHC I antigen presentation requires peptides generated in the proteasome to be transported into the endoplasmic reticulum (ER) through the TAP1/TAP2 heterodimer, bind MHC I molecules, and then move to the cell surface.

TAP1, TAP2 variants

The most common cause is pathogenic variants in the TAP1 (6p21.32) or TAP2 (6p21.32) gene. TAP (Transporter associated with Antigen Processing) is a heterodimeric ABC transporter that carries peptides into the ER. In TAP deficiency, peptide loading does not occur, so MHC I molecules cannot be stably expressed on the cell surface.

Tapasin (TAPBP) variants

Tapasin is a chaperone protein that links TAP and MHC I molecules, and variants in this gene (6p21.3) also cause MHC I deficiency. Compared with TAP variants, patients with Tapasin variants tend to have milder clinical symptoms.

3. Genetics

Mode of inheritance and gene location

Inheritance is autosomal recessive. The TAP1, TAP2, and TAPBP genes are all located in the MHC region of the short arm of chromosome 6 (6p21). When both parents are carriers, 25% of their children are affected.

Molecular diversity

TAP1 variants are identified in the largest number of patients, mostly premature termination or deletion variants. TAP2 variants and Tapasin variants have also been reported. Recurrent variants due to a founder effect have been reported within the same populations (especially in North Africa and the Middle East).

Clinical variability

Clinical severity differs even among patients carrying the same genetic variant, so environmental factors and individual differences in immune response are presumed to influence the phenotype.

4. General epidemiology

Worldwide prevalence

MHC class I deficiency is a very rare primary immunodeficiency, with fewer than 50 cases reported worldwide. The exact prevalence is unclear and is estimated at less than 1 in several million births.

Regional clustering

Clustering of founder variants due to consanguineous marriage has been reported in North Africa (Morocco, Algeria) and the Middle East. Sporadic cases have also been reported in Europe.

Age at onset

Compared with MHC II deficiency, clinical symptoms of MHC I deficiency appear later, and some cases are diagnosed in late childhood (5–10 years) or adulthood. This is because, although CD8+ T cells are absent, NK cell function is partly maintained, so defense against early infections is preserved to some degree.

Status in Korea

In Korea, diagnosed cases of MHC I deficiency are extremely rare, and patients are managed at hospitals specializing in primary immunodeficiency.

5. Pathophysiology

Mechanism of absent MHC I expression

In TAP1/TAP2 deficiency, peptides degraded in the proteasome cannot be transported into the ER, so MHC I molecules cannot load appropriate peptides. Without peptides, the MHC I-β2-microglobulin complex becomes unstable, and cell surface expression is markedly reduced.

Impaired CD8+ T-cell development

MHC I molecules on thymic cortical cells are essential for positive selection of CD8+ T cells in the thymus. In MHC I deficiency, intrathymic positive selection of CD8+ T cells is impossible, and CD8+ T cells are markedly reduced or absent in peripheral blood.

Interaction with NK cell activating receptors

MHC I molecules act as ligands for NK cell inhibitory receptors (KIR, NKG2A, etc.), suppressing NK cell killing of normal self cells. MHC I-deficient cells can be killed by NK cells, but at the same time NK cell activity is compensatorily increased, providing partial defense against viral infection.

Susceptibility to viral infection

Because the cytotoxic CD8+ T-cell response that is key to defense against intracellular viral infection is lacking, chronic viral infection (especially viral obstructive lung disease) emerges as the main clinical problem.

6. Symptoms

Recurrent respiratory infections and obstructive lung disease

The most characteristic symptom of MHC I deficiency is recurrent upper and lower respiratory tract infection, which often progresses to chronic suppurative lung disease, bronchiectasis, and obstructive lung disease. Bacterial infections (pneumococcus, Haemophilus, Staphylococcus aureus) and viral infections (especially parainfluenza, RSV, adenovirus) are frequent.

Late onset of immunodeficiency symptoms

Symptoms appear later than in MHC II deficiency, and some cases are first diagnosed at school age or in adulthood. Initially it presents with mild recurrent infections and gradually worsens.

Skin and other infections

Viral skin infections (herpes zoster, herpes simplex virus) and eye infections have been reported. In severe cases, disseminated BCG infection may develop after BCG vaccination.

Autoimmune symptoms

Autoimmune complications such as cutaneous vasculitis and autoimmune hepatitis have been reported in some patients.

7. Signs

Physical examination findings

Crackles and wheezes due to chronic lung disease are heard on auscultation. In severe lung disease, clubbing and chest wall deformity may appear. Nasal congestion, purulent rhinorrhea, and facial tenderness due to chronic sinusitis are found.

Immunological test findings

Lymphocyte subset analysis is characterized by marked reduction or absence of CD8+ T cells. CD4+ T cells are normal or mildly reduced, and B cells are normal. Serum immunoglobulins (IgG, IgA, IgM) are generally normal. Flow cytometry shows marked reduction or loss of HLA class I molecule expression on the lymphocyte surface.

Imaging findings

Chest CT shows bronchiectasis, atelectasis, and findings of chronic pulmonary insufficiency. Findings of chronic sinusitis on sinus CT are common.

8. Screening

Clinical suspicion

Primary immunodeficiency should be suspected in children or adults with recurrent respiratory infections and chronic lung disease. Family history (parental consanguinity, similar symptoms in siblings, infant deaths) is checked.

Basic immunological tests

The complete blood count may show lymphopenia but can also be normal. Confirming whether CD8+ T cells are reduced or absent by flow cytometry is the first screening step.

HLA class I expression testing

Cell surface expression of HLA-A, -B, and -C molecules is measured by flow cytometry. Expression reduced to less than 5% of normal strongly suggests MHC I deficiency.

Status in Korea

In Korea there is no systematic screening program for MHC I deficiency, and the diagnosis is made by immunological testing in patients referred for recurrent infections. TREC-based newborn screening may miss some patients with MHC I deficiency, so a complementary approach is needed.

9. Diagnosis

Flow cytometry

The key diagnostic finding is marked reduction or loss of lymphocyte surface expression on flow cytometry using HLA class I (HLA-A, B, C) antibodies. A reduction in CD8+ T cells is confirmed at the same time.

TAP function tests

Intracellular TAP protein expression is confirmed by Western blot or flow cytometry (intracellular antibody staining). Functional TAP transport capacity can also be measured using radioisotope- or fluorescence-labeled peptides.

Molecular genetic testing

Pathogenic variants are identified by sequencing of the TAP1, TAP2, and TAPBP genes or by NGS panel testing. Identification of two pathogenic variants (homozygous or compound heterozygous) is the criterion for confirmation.

Differential diagnosis

MHC I deficiency must be differentiated from MHC II deficiency (with reduced CD4+ T cells), SCID (pan-lymphopenia), and HIV infection (reduced CD4+ T cells).

10. Treatment

Hematopoietic stem cell transplantation (HSCT)

The curative treatment for MHC I deficiency is allogeneic hematopoietic stem cell transplantation. After transplantation, normal donor-derived T cells and NK cells reconstitute and immune function can recover. However, the earlier it is performed, the more pre-transplant lung damage from chronic lung disease limits the prognosis.

Prevention and treatment of infection

Recurrent infections are prevented with prophylactic antibiotics (azithromycin, etc.), antifungals, and antivirals. Chronic lung disease is managed with respiratory physiotherapy, bronchodilators, inhaled steroids, and similar measures.

Immunoglobulin therapy

When serum immunoglobulin levels are below normal, IVIG replacement therapy is given.

Adjunctive treatment

Chronic sinusitis is managed with antibiotics and otolaryngologic surgery. If needed, bronchoscopic lavage and suction are performed. Live vaccines are contraindicated.

11. Prognosis

Long-term prognosis

Without treatment, chronic lung disease and bronchiectasis due to recurrent respiratory infections progress, and death from respiratory failure may occur. The prognosis of MHC I deficiency is relatively better than that of MHC II deficiency, but if diagnosis is delayed, lung damage progresses irreversibly.

Prognosis after transplantation

Immune function can recover after successful HSCT, but lung damage that has already progressed persists after transplantation. Early diagnosis and early transplantation are decisive for preserving lung function.

Prognosis of patients with Tapasin variants

Cases due to Tapasin variants have a milder clinical course than those due to TAP variants, and some patients have been reported to reach adulthood without respiratory complications.

12. Prevention

Genetic counseling

Because inheritance is autosomal recessive, carrier testing of both parents and genetic counseling are needed.

Prenatal diagnosis

In pregnant women with a family history, the fetal genotype can be confirmed by chorionic villus sampling or amniocentesis. PGT-M can prevent implantation of affected embryos.

Contraindication of live vaccines

Live vaccines such as BCG, MMR, and varicella are absolutely contraindicated.

Minimizing exposure to infection

After early diagnosis and until transplantation, exposure to infection is minimized and prophylactic anti-infective therapy is strictly maintained. When symptoms of respiratory infection occur, treatment is started immediately to minimize lung damage.

Newborn screening and early diagnosis

Early detection of MHC I deficiency is possible with TREC-based newborn screening (TREC is reduced in some TAP deficiencies), and when it is suspected, prompt immunological confirmatory testing is performed.

13. References

  1. Touraine JL, Betuel H, Souillet G, et al. Combined immunodeficiency disease associated with absence of cell-surface HLA-A and HLA-B antigens. J Pediatr. 1978;93(1):47-51.
  2. de la Salle H, Hanau D, Fricker D, et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science. 1994;265(5169):237-241.
  3. Gadola SD, Moins-Teisserenc HT, Trowsdale J, et al. TAP deficiency syndrome. Clin Exp Immunol. 2000;121(2):173-178.
  4. Zimmer J, Andres E, Donato L, et al. Clinical and immunological aspects of HLA class I deficiency. QJM. 2005;98(10):719-727.
  5. Moins-Teisserenc HT, Gadola SD, Cella M, et al. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet. 1999;354(9190):1598-1603.
  6. Galy A, Vernie MT, de Villartay JP, et al. A case of combined immunodeficiency due to HLA class I molecule expression deficiency. Eur J Immunol. 1988;18(12):1913-1917.
  7. Zimmer J, Donato L, Hanau D, et al. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med. 1998;187(1):117-122.
  8. Yabe T, Kawamura S, Sato M, et al. A subject with a novel type I bare lymphocyte syndrome has tapasin deficiency due to deletion of 4 exons by Alu-mediated recombination. Blood. 2002;100(4):1496-1498.
  9. Picard C, Al-Herz W, Bousfiha A, et al. Primary immunodeficiency diseases: an update on the classification from the IUIS Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35(8):696-726.
  10. Trowsdale J, Knight JC. Major histocompatibility complex genomics and human disease. Annu Rev Genomics Hum Genet. 2013;14:301-323.
  11. Lo WF, Donahue K, Adams EJ. The structural basis for peptide selection by tapasin. Immunity. 2009;31(5):748-759.
  12. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749-795.